Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Business Wire
The collaboration between Multiply Labs and Legend Biotech will focus on applying advanced robotic technology to the manufacturing of cell therapy platforms SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced the launch of its collaboration with Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in the cell therapy space. This initiative will be focused on automating cell therapy manufacturing, leveraging Multiply Labs’ unique approach which consists of robotic systems that can operate a wide variety of instruments already deployed in the cell and gene therapy industry. This collaboration holds the potential to enable a more rapid and seamless adoption of robotic technology, as opposed to traditional automation approaches that require substantial changes to the manufacturing process.This press release features multimedia. View the full
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"PR Newswire
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line [Yahoo! Finance]Yahoo! Finance
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineGlobeNewswire
- Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.MarketBeat
- Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion [Seeking Alpha]Seeking Alpha
LEGN
Earnings
- 5/13/24 - Beat
LEGN
Sec Filings
- 9/27/24 - Form 6-K
- 9/25/24 - Form 144
- 9/20/24 - Form 144
- LEGN's page on the SEC website